Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder

Fineline Cube Feb 12, 2026
Company Deals

uBriGene Biosciences Partners with BriSTAR Immunotech on Universal STAR-T Cell Therapy CDMO

Fineline Cube Feb 12, 2026
Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Fineline Cube Feb 11, 2026
Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy

Fineline Cube Feb 12, 2026
Company Drug

Hengrui’s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China

Fineline Cube Feb 12, 2026
Company Deals R&D

Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration

Fineline Cube Jan 5, 2023

US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced...

Policy / Regulatory

China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan

Fineline Cube Jan 5, 2023

The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have...

Company Deals

Zhongchao Partners with Natco Pharma to Distribute Drugs in China

Fineline Cube Jan 5, 2023

Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with...

Company Deals

By-Health to Establish Nutrition Research Center with Shanghai Institute

Fineline Cube Jan 5, 2023

China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and...

Company Deals

CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA

Fineline Cube Jan 4, 2023

China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to...

Company Drug

Transcenta’s TST003 Receives Clinical Trial Approval in China and US

Fineline Cube Jan 4, 2023

China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...

Company Drug

Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications

Fineline Cube Jan 4, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline

Fineline Cube Jan 4, 2023

China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion...

Company Drug

HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP

Fineline Cube Jan 4, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...

Company Drug

RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer

Fineline Cube Jan 4, 2023

China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...

Company Deals

Apeloa and Simcere Partner for CDMO Services and R&D Collaboration

Fineline Cube Jan 4, 2023

China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739)...

Company Deals

Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5

Fineline Cube Jan 4, 2023

China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia...

Company Deals

Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds

Fineline Cube Jan 4, 2023

Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully...

Company

Everest Medicines Outlines Strategic Plans for Expansion and Growth

Fineline Cube Jan 4, 2023

China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for...

Company

Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D

Fineline Cube Jan 4, 2023

Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of...

Company Drug

Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors

Fineline Cube Jan 4, 2023

China – based Jiangxi Jemincare Group has announced that it has received approval from the...

Company Drug

Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases

Fineline Cube Jan 4, 2023

China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has...

Company Drug

Staidson’s Anti-C5a Monoclonal Antibody STSA-1002 Accepted for NMPA Review

Fineline Cube Jan 3, 2023

China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced that the clinical trial filing...

Company Deals

Guangdong Raynovent Biotech Secures RMB 370 Million in Series C Financing

Fineline Cube Jan 3, 2023

Guangdong Raynovent Biotech Co., Ltd, a controlling subsidiary of China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd...

Company

Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO

Fineline Cube Jan 3, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun...

Posts pagination

1 … 536 537 538 … 623

Recent updates

  • Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy
  • Hengrui’s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China
  • Eli Lilly’s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China
  • Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder
  • uBriGene Biosciences Partners with BriSTAR Immunotech on Universal STAR-T Cell Therapy CDMO
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Eli Lilly’s Jaypirca Wins NMPA Approval for CLL/SLL Post-BTK Inhibitor Therapy

Company Drug

Hengrui’s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China

Company Drug

Eli Lilly’s Mounjaro Wins NMPA Monotherapy Approval for Type 2 Diabetes in China

Company Deals

Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.